tegafur has been researched along with Carcinoma, Ductal, Breast in 16 studies
Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study assesses the effects of neo-adjuvant chemotherapy (NAC) with uracil and tegafur (UFT) alone vs UFT plus cyclophosphamide (CPA), on the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in breast cancer tissues." | 5.12 | Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. ( Fukushima, M; Hashimoto, K; Iguchi, C; Itakura, M; Kodama, H; Koike, M; Maruyama, R; Nio, Y; Toga, T, 2007) |
| "We had 2 patients with marked shrinkage of liver metastasis by administration of the oral fluorinated pyrimidine anticancer drug S-1 for advanced/recurrent breast cancer that was resistant to taxane and another antitumor drugs." | 3.73 | [Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs]. ( Sato, Y, 2006) |
| " Because salvage therapy with S-1 alone showed good antitumor efficacy and beneficial tolerability when the standard dosage was maintained, it was considered that this home therapy was effective for advanced/recurrent breast cancer that was resistant to anthracycline and taxane antitumor drugs." | 1.33 | [Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer]. ( Itoh, K; Minami, H, 2005) |
| "We experienced a case of recurrent breast cancer resistant to prior medications, which was treated with oral S-1, a fluoropyrimidine-class anticancer drug, and exhibited the marked shrinkage of liver metastasis." | 1.33 | [A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer]. ( Mitsuyama, S; Nishihara, K, 2006) |
| "S-1 could be a valuable agent for breast cancer treatments, since it showed clinical efficacy and mild toxicity, and can be given orally." | 1.33 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. ( Aogi, K; Doihara, H; Nishimura, R; Ohsumi, S; Saeki, T; Taira, N; Takashima, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanigawa, T | 1 |
| Miyamoto, Y | 1 |
| Abe, M | 1 |
| Hasuo, T | 1 |
| Doiguchi, M | 1 |
| Sakamoto, F | 1 |
| Yoshida, H | 1 |
| Yamamoto, D | 1 |
| Kanematsu, S | 1 |
| Tanaka, K | 1 |
| Ah, K | 1 |
| Katsuta, E | 1 |
| Ohkubo, T | 1 |
| Someno, Y | 1 |
| Saguchi, M | 1 |
| Aoyagi, H | 1 |
| Takahata, T | 1 |
| Hasegawa, K | 1 |
| Hamada, S | 1 |
| Kaneko, J | 1 |
| Maejima, S | 1 |
| Hashimoto, K | 2 |
| Nio, Y | 2 |
| Koike, M | 2 |
| Itakura, M | 2 |
| Yano, S | 1 |
| Higami, T | 1 |
| Itoh, K | 1 |
| Minami, H | 1 |
| Nishihara, K | 1 |
| Mitsuyama, S | 1 |
| Sato, Y | 1 |
| Sato, N | 1 |
| Sano, M | 1 |
| Taira, N | 1 |
| Aogi, K | 1 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Nishimura, R | 1 |
| Doihara, H | 1 |
| Saeki, T | 2 |
| Nakajima, H | 1 |
| Mizuta, N | 1 |
| Mizuta, M | 1 |
| Nakatsukasa, K | 1 |
| Kobayashi, A | 1 |
| Hachimine, Y | 1 |
| Sakaguchi, K | 1 |
| Fujiwara, I | 1 |
| Sawai, K | 1 |
| Iguchi, C | 1 |
| Kodama, H | 1 |
| Toga, T | 1 |
| Maruyama, R | 1 |
| Fukushima, M | 1 |
| Yoshimura, Y | 1 |
| Tawara, K | 1 |
| Yoshigi, J | 1 |
| Nagaoka, S | 1 |
| Rai, Y | 1 |
| Emi, Y | 1 |
| Nishijima, N | 1 |
| Kai, S | 1 |
| Kano, T | 1 |
| Kusama, M | 1 |
| Kaise, H | 1 |
| Nakayama, S | 1 |
| Oota, D | 1 |
| Aoki, T | 1 |
| Koyanagi, Y | 1 |
| Matsunaga, T | 1 |
| Nakamura, Y | 1 |
| Ishihama, H | 1 |
2 reviews available for tegafur and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
[Clinical benefit of S-1 in metastatic breast cancer].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, | 2006 |
Concomitant salivary duct carcinoma of a minor buccal salivary gland and papillary cystadenoma lymphomatosum of a cervical lymph node: report of a case and review of the literature.
Topics: Adenolymphoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Chemothera | 1995 |
1 trial available for tegafur and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2007 |
13 other studies available for tegafur and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
[A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
[A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Combinations; Dru | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; An | 2010 |
[A case of liver metastases of breast cancer successfully treated by combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab].
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2004 |
[Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Rin | 2005 |
[A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ri | 2006 |
[Two patients effectively treated with S-1 therapy for liver metastasis of breast cancer resistant to other anticancer drugs].
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Rin | 2006 |
[Successful monotherapy with S-1 in three cases of recurrent/advanced breast cancer non-responsive to anthracycline and taxane anticancer drugs].
Topics: Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Brid | 2006 |
S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 2006 |
[A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
[A patient with hepatic metastasis of breast cancer successfully treated with combined chemoendocrine therapy using epirubicin, tegafur and tamoxifen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Ad | 1999 |
[A case of postoperative lung and pleural recurrence after 20 years in a breast cancer patient with marked response to orally administered UFT and cyclophosphamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2001 |